Hemay808 is a dual inhibitor targeting IgE and PDE4, formulated as a topical ointment, intended for the treatment of atopic dermatitis (AD).
Atopic dermatitis (AD), also known as eczema, is a chronic, relapsing, inflammatory skin condition that predominantly affects infants and children but can also occur in adults. The pathogenesis of AD is complex and primarily associated with genetic predisposition, environmental irritants, epidermal barrier defects, and immune dysregulation. Disruption of the epidermal barrier triggers inflammatory responses, with Th2 cells becoming activated and dominant during the acute phase, producing cytokines such as IL-4, which induce B cells to generate IgE, leading to degranulation of mast cells and basophils. During the chronic phase, there is more extensive infiltration of inflammatory cells, including both Th2 and Th1 cells.
Hemay808 is currently undergoing clinical trials for this indication in China. For detailed information on related clinical trials, please visit CLINICALTRIALS.GOV.
